The Corona pandemic demands protection from infection. These measures represent an essential change to the way people with spinal muscular atrophy (SMA) are cared for. In such scenarios, the
The study on Nusinersen is a nation-wide, systematic patient interview conducted with 100 patients with Spinal Muscular Atrophy (SMA) with the objective of gaining important new insights into
Nusinersen (Spinraza®) is an approved drug for the treatment of 5q-associated Spinal Muscular Atrophy (SMA). Infants and children treated with Nusinersen may experience cessation of disease